早期确认性检测对主动监测前列腺癌患者升级及转治疗的影响
基于MUSIC登记数据,纳入2,514例接受主动监测的低危前列腺癌男性,其中48%接受了确认性检测(重复活检、基因组检测、MRI或MRI后活检)。确认性检测结果令人安心者 surveillance 活检再分类风险更低(HR 0.57),且维持主动监测时间更长;结果不令人安心者再分类风险升高(HR 1.97)。
要点
- 确认性检测结果令人安心者12个月活检无再分类概率90%,不令人安心者68%。
- 令人安心者24个月无治疗概率79%,不令人安心者55%。
- 确认性检测有助于对考虑主动监测者进行风险分层。
核心结论
- 确认性检测结果令人安心的低危前列腺癌患者 surveillance 活检再分类更少且维持主动监测更久。
研究设计与样本
- 回顾性队列研究,从MUSIC登记中筛选2,514例接受主动监测的低危前列腺癌男性,其中1,211例(48%)接受了确认性检测。
主要发现
- 12个月未调整 surveillance 活检无再分类概率:不令人安心组68%、无确认性检测组83%、令人安心组90%(P < .0001)。
- 24个月未调整无治疗概率:不令人安心组55%、无确认性检测组81%、令人安心组79%(P < .0001)。
- 多变量模型中,排除基因组确认性检测后,令人安心组 surveillance 再分类风险低于无确认性检测组(HR 0.57,95%CI 0.38-0.84,P = .005)。
- 不令人安心组 surveillance 再分类风险高于无确认性检测组(HR 1.97,95%CI 1.22-3.19,P = .006)。
临床怎么用
- 对于考虑主动监测的低危前列腺癌患者,可借助确认性检测进行风险分层。
- 确认性检测结果令人安心者更可能长期维持主动监测,结果不令人安心者需更密切监测或考虑治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the impact of confirmatory tests on active surveillance (AS) biopsy disease reclassification and progression to treatment in men with favorable risk prostate cancer (FRPC). METHODS: We searched the MUSIC registry for men with FRPC managed with AS without or with a confirmatory test. Confirmatory tests included (1) repeat prostate biopsy, (2) genomic tests, (3) prostate magnetic resonance imaging (MRI), or (4) MRI followed by a post-MRI biopsy. Confirmatory test results were deemed reassuring (RA) or nonreassuring (nonRA) according to predefined criteria. Kaplan-Meier curves and multivariable Cox regression models were used to compare surveillance biopsy disease reclassification-free survival and treatment-free survival. RESULTS: Of the 2,514 men with FRPC who were managed on AS, 1211 (48%) men obtained a confirmatory test. We noted differences in the 12-month unadjusted surveillance biopsy disease reclassification-free probability (68%, 83%, and 90%, P < .0001) and 24-month unadjusted treatment-free probability (55%, 81%, and 79%, P < .0001), for men with nonRA confirmatory tests, no confirmatory test, and RA confirmatory tests, respectively. Excluding patients with genomic confirmatory tests, men with RA confirmatory tests were associated with a lower hazard (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.38-0.84, P = .005) and men with nonRA confirmatory tests had an increased hazard (HR 1.97, 95% CI 1.22-3.19, P = .006) of surveillance disease reclassification compared with men without confirmatory tests in the multivariable model. CONCLUSION: These data suggest men with RA confirmatory tests have less surveillance biopsy reclassification and remain on AS longer than men with nonRA test results. Confirmatory tests may help risk stratify men considering active surveillance.
引用
- Ginsburg KB, Jacobs JC, Qi J, et al. Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance. Urology. 2020. PMID: 32946908. doi:10.1016/j.urology.2020.07.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。